Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study
Authors' conclusion
The SEMALEAN study highlights the significant impact of Semaglutide 2.4 mg on weight loss, fat mass reduction, and muscle function improvement, with preserved lean mass and metabolic efficiency. These findings underscore the importance of a comprehensive approach to obesity management, addressing not only weight loss but also functional and metabolic adaptation.
Study context
- Population
- Patients with obesity, enrolled February 2022–November 2024; 68.9% female, mean BMI 46.3 kg/m²106 completed
- Participants
- 115 patients
- Outcome
- Body weight reduction
- Follow-up
- M7 and M12
Methodological detailssingle-arm, subgroup analyses
- Single-arm
- Subgroup analyses
Main finding
As reported in the abstract
Mean weight reduction at M7
10%
Mean weight reduction at M12
13%
Achieved ≥10% weight loss
59%
Observational data: associations, not effects.
Further findings
Subgroups: sex, T2D, prior GLP-1 use, bariatric surgery
- Greater weight and fat mass loss in women
- Attenuated responses with T2D or prior GLP-1 analogue use
- Most pronounced body composition reductions with history of bariatric surgery
Original publication
Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes Obes Metab. Published 9 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →